Views & Analysis Future prospects for an Innovative Medicines Fund for Englan... On the 12 December 2019, the UK general public voted for a further five years of Conservative government.
News New price gets Clovis’ PARP inhibitor on the CDF NICE has reversed its decision on Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) and will allow the drug to be used on the Cancer Drugs Fund (CDF), after the manufacturer offered a lower p
Views & Analysis NICE’s track record in cancer drugs: the impact of the CDF a... Leela Barham looks back to before the Cancer Drugs Fund and how recommendations have changed through CDF 1.0 and CDF 2.0 to explore it's success.
Views & Analysis Pharma’s new ‘sensible pricing’ behind cancer drug approvals... A string of 'yes' decisions from NICE on cancer drugs - but what has changed?
Debates & Insight Sponsored Finding a cure: Getting the best Brexit deal for Britain’s l... Four months have now elapsed since the UK voted to leave the EU.
Views & Analysis A novel UK approach to cancer access: yes, no, or maybe? Experts discuss the implications of the new, reinvigorated Cancer Drugs Fund, for pharma and patients.
News PBM reform dropped in Congress' funding package Proposed reforms to the regulations for PBMs were dropped from the US Congress' end-of-year bill to provide funding to the federal government.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
